➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Baxter
AstraZeneca
Boehringer Ingelheim
Moodys

Last Updated: August 5, 2020

DrugPatentWatch Database Preview

BILTRICIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Biltricide, and when can generic versions of Biltricide launch?

Biltricide is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in BILTRICIDE is praziquantel. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the praziquantel profile page.

US ANDA Litigation and Generic Entry Outlook for Biltricide

A generic version of BILTRICIDE was approved as praziquantel by PAR PHARM INC on November 27th, 2017.

  Start Trial

Drug patent expirations by year for BILTRICIDE
Drug Prices for BILTRICIDE

See drug prices for BILTRICIDE

Recent Clinical Trials for BILTRICIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 1
Merck KGaA, Darmstadt, GermanyPhase 3
Merck KGaAPhase 1

See all BILTRICIDE clinical trials

Pharmacology for BILTRICIDE
Drug ClassAnthelmintic

US Patents and Regulatory Information for BILTRICIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare BILTRICIDE praziquantel TABLET;ORAL 018714-001 Dec 29, 1982 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Boehringer Ingelheim
Medtronic
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.